Hospira received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending European Commission approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.
Inflectra (infliximab) is a biosimilar medicine to the reference medicinal product, Remicade (infliximab), and is the first monoclonal antibody therapy to reach a positive opinion following review via the EMA biosimilars regulatory pathway. A biosimilar developed in-line with EU requirements can be considered a therapeutic alternative to an existing biologic, with comparable quality, efficacy and safety to the reference product.
Biologic medicines have led to vast improvements in the treatment of conditions such as rheumatoid arthritis and inflammatory bowel disease, but they also represent one of the biggest medical expenditures in many countries.
Inflectra specifically targets tumor necrosis factor (TNF) alpha, a protein in the body that contributes to the painful inflammation seen in rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. The drug's safety, efficacy and tolerability have been established through a comprehensive clinical trial program. In a phase III randomized, double-blind study, Inflectra met its primary endpoint of therapeutic equivalence to the reference product. In the study, 73.4% of patients receiving Inflectra achieved a greater than 20% improvement in RA symptoms after 30 weeks of treatment (using the ACR20 scoring system), compared with 69.7% treated with reference infliximab. The safety and tolerability of Inflectra was also demonstrated to be comparable to Remicade, supporting its approval.
In 2009, Hospira entered into an agreement with South Korean-based biopharmaceutical company, Celltrion, which is developing eight monoclonal antibody biosimilars. Under the terms of the agreement, Hospira obtained the rights to Inflectra in Europe, the United States, Canada, Australia and New Zealand.
The European Commission reviews the recommendations of the CHMP. The final decision on approval, usually granted within three months of CHMP opinion, will be applicable to all European Union (EU) and European Economic Area (EEA) countries.
Hospira is the only U.S.-based company with biosimilars on the European market, including Retacrit which was launched in Europe in early 2008 and Nivestim, which entered the European market in 2010 and Australian market in 2011.
"In a time when there is mounting pressure on healthcare budgets worldwide, Inflectra provides an opportunity to increase patient access to more affordable biologic therapy while maintaining high quality standards," said Richard Davies, Senior Vice President and Chief Commercial Officer, Hospira.
 Weise M. et al. Blood. 2012; 120: 5111-5117
 Bendtzen, K. Immunotherapy. 2012; 4(11): 1167-1179.
 Hospira Inc, 2013, Data on file.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- How A Former Naturopath Can Help Unravel The Trickery of Alternative Medicine
- Nanotech: The Most Dangerous Science Least Carefully Done
- Can A New Rule Trigger A Second EU Referendum? Petition Signatures Over 11% Of Total Votes Cast
- A Billion Years Ago, What Did Earth's Ancient Magnetic Field Look Like?
- Better Brains With Beer
- Finding All-Hadronic Top - Again
- How A Woman With Amnesia Defies Conventional Wisdom About Memory
- "If you really wanted to know the truth you could find many researched and peer reviewed articles..."
- "So how many people with HIV, HCV, Parkinson's, MS, Hansen's disease, etc etc etc are being cured..."
- "Hi Robert; Hope you are doing well. Just wanted you to know that I've put up a new video regarding..."
- "so in a nutshell basically they're not taking worries seriously..."
- "Sentence makes perfect sense. Has it been fixed?..."
- Swayed By Lunch Money: A Grotesque Insult to Doctors
- Sensing Too Much Zika Exposure, Golfers Continue Olympic Exodus
- Cannabis Beverages: A New Way to Get High
- Got Zika? Thank an Environmentalist
- Magical Moron Moments: Burn Your Feet with Tony Robbins
- IARC is controversial – because they put ideology over science
- LGBT rights and protections are scarce in constitutions around the world, UCLA study finds
- Bacterial colonies in human body linked to presence of cancer in mouth and throat
- The Smithsonian celebrates the Panama Canal expansion
- What happens when you steam a planet?
- Clandestine black hole may represent new population